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Abstract
Background: Persistent high-risk type Human papillomavirus (HPV) infection is recognized as a necessary cause of cervical
cancer. This study aimed to compare the HPV prevalence and risk factors between women residing in Hong Kong (HK) and
Guangzhou (GZ) region of China.
Methodology/Principal Findings: A total of 1,570 and 1,369 women were recruited from HK and GZ, respectively. The
cytology samples were collected and tested for HPV infection. The overall and type-specific HPV prevalence and the
potential risk factors for acquisition of HPV infection were studied. Women with normal cytology in the GZ cohort had
significantly higher HPV prevalence (10%) than those in the HK cohort (6.2%, p,0.001). The patterns of the age-specific HPV
prevalence were also different between the two cohorts. In the HK cohort, women at the age of 20–29 years old had the
highest prevalence and a second peak was observed in the age of $60 years old. In the GZ cohort, the highest HPV
prevalence was also observed in 20–29 years old but declined as the age increased and a second peak was not seen. HPV16
and HPV52 were the most common high-risk types found in the HK and GZ cohorts, respectively. Age was the most
consistently observed independent risk factor for HPV infection in the HK, while the number of sexual partners had
association in the GZ cohort.
Conclusions/Significance: Our study provides the current status and the epidemiological characteristics of HPV prevalence
in Southern Chinese women. The results strongly suggested that population education and the effective cervical cancer
screening would be vital in the prevention of cervical cancer.
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Introduction
Cervical cancer is the second most common woman cancer
worldwide, but it is ranked first in South Asia [1]. Epidemiological
and molecular studies have shown that genital HPV is the main
etiological factor for the disease [2,3]. HPV is a common sexually
transmitted pathogen that plays an important role in the
pathogenesis of pre-cancerous cervical lesion and cervical cancer
[2,4]. More than 100 types of HPVs have been identified and
about 40 of them are found associated with lesions of the female
genital tract. Persistent infection with one of 13 high-risk HPV
types causes almost all cervical cancers [5]. Knowledge of HPV
status becomes more important as it can be used as a primary
screening method for cervical cancer, and for triage of women
with atypical or borderline cervical smears.
Analysis of worldwide distribution of HPV types on the four
continents, Asia, Africa, Europe and South America, showed that
HPV prevalence varied as much as 20 times among populations in
different geographic regions [5,6]. Focusing on the Southeast Asian
countries, the prevalence ranged from 1.6% in Hanoi Vietnam to
13.3% in Korea [6]. Within the Chinese populations, HPV
prevalence and subtype distribution in cervical lesions and invasive
cancer differed amongst different geographic areas in mainland
China [7–9]. The prevalence of certain HPV types in Hong Kong
(HK), especially HPV16 variants, was also different from that
reported in Sichuan, China [10]. The HPV16 isolated from Sichuan
had the closest similarity to Asian-American and Asian lineages [11],
whereas the most prevalent HPV16 variant found in HK were of
Asian and European lineages [12]. HK has been a British colony and
it had been the gateway for trading with the West for centuries. This
may explain the prevalence of European variants in this area.
The incidence and mortality of cervical cancer were ranked the
fifth and the ninth respectively amongst all cancers in HK women
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in 2006. There were 459 new cases and 133 death reported.
Although a decline in incidence and mortality of cervical cancer
was reported in mainland China in the 1970s [13–16], the
mortality was found increased in young women, particular in
urban areas, which was suggested to be a reflection of the changes
in the sexual behaviours [16]. This was evident by the increased
incidence of sexually transmitted diseases in China in 1990s [17].
The epidemiology of HPV genotypes in Guangzhou (GZ), one of
HK’s closest neighbouring cities, has not yet been studied.
Following the economical growth and improved transportation
between HK and mainland China, especially the GZ regions,
cross-boundary marriages and travelling have tremendously
increased in the last decade. As a result, common infectious
diseases are easily transmitted across the border. In the present
study, we aimed to study and compare the spectrum and the
prevalence of HPV infection in women living in HK and GZ
regions, and to identify potential risk factors in both regions.
Results
Characteristics of the study population
A total of 1570 and 1369 women were recruited in HK and GZ,
respectively. Those with abnormal cytological findings (44 in HK
and 69 in GZ) were excluded from the study. HPV prevalence
analyses were performed on 1526 (HK) and 1330 (GZ) cases,
whose genomic DNA was successfully extracted for HPV detection
and genotyping, and the correlation analyses were performed on
1330 (HK) and 1233 (GZ) cases as these cases had all of the
potential risk factors data available for statistical analysis.
Most women in both HK and GZ cohorts had intermediate
(secondary/post-secondary) or high (college/university or above)
education levels (78% in HK and 89% in GZ), had their first
sexual activity before the age of 25 (76% in HK and 67% in GZ)
and one lifetime sexual partner (69% in HK and 86% in GZ). Few
women smoked (12% in HK and 3% in GZ) or had a history of
sexually transmitted disease (,2% in both cohorts). Only 31% of
women in the GZ cohort had previous cervical smear test; in
contrast, 84% of women in the HK cohort had the test previously.
This relative low value in the GZ cohort would be due to the fact
that, unlike HK, GZ had no cervical screening programme
provided to the community. The use of contraceptive methods was
also different between the two cohorts, where 45% and 86% of
women used a contraceptive method other than the oral
contraceptive pills. Two thirds of women in the GZ cohort had
a previous termination of pregnancy or miscarriage (69%), while
one third was observed in the HK cohort (34%).
HPV prevalence in the Hong Kong and Guangzhou
cohorts
The overall HPV prevalence in women with normal cytology
between the two cohorts was significantly different (6.2%, 95% CI:
5.1–7.3% for HK and 10%, 95% CI: 8.4–11.5% for GZ,
p,0.001). The middle-aged groups (30–59 years old) in the GZ
cohort had significantly higher HPV prevalence (p,0.001-
p = 0.007) than that in the HK cohort (Fig. 1A). In the GZ
cohort, the 20–29 age-group was found to have the highest HPV
prevalence (15.1%, 95% CI: 10.7–19.5), and the prevalence
declined as the age increased, and there was no significant
difference observed in HPV prevalence among the five age-
groups. Interestingly, a two peak (bimodal distribution) pattern of
HPV prevalence was observed in the HK cohort. Women below
the age of 29 had the highest HPV prevalence (13%), which was
significantly higher than that in the middle-aged women among
age-groups of 30–59 years old (HPV prevalence of 4.9% for 30–
39, 4.6% for 40–49, and 7.1% for 50–59 age-groups, p = 0.0003,
0.0001, and 0.011, respectively), and there was a less pronounced
second peak of HPV infection (Fig. 1A) in women over the age of
60 years (9.6%), which was significantly higher compared to
women in the 30–39 age-group (4.9%) (p= 0.029).
High-risk HPV types comprised more than 2/3 of the HPV
infection in both of our cohorts. The GZ cohort had significantly
higher high-risk type HPV prevalence (7.5%) than those in the
HK cohort (4.2%, p,0.001). The patterns of high-risk HPV
prevalence were similar to that of overall HPV prevalence in the
two cohorts (Fig. 1B), a significant difference between the two
cohorts was observed in women in the 30–49 age-groups
(p,0.001). In the HK cohort, the high-risk type HPV prevalence
also followed a bimodal distribution with the highest peak
appearing in the 20–29 age-group (9.1%) and the second peak
appearing in$50 age-groups (5.9%–6.4%). The 30–39 and 40–49
age-groups had significantly lower prevalence (3.1% and 2.3%,
respectively) than other age-groups (p = 0.02–0.002). No signifi-
cant difference in the high-risk HPV prevalence was found among
the five age-groups in the GZ cohort, and the highest prevalence
was in 30–39 age-group.
The prevalence of multiple HPV infections was 1.8% and 1.7%
for the HK and GZ cohorts, respectively, accounting for 30.6%
Figure 1. Comparison of the age-specific overall and high-risk
HPV prevalence in five age-groups in the HK and GZ cohorts.
(A) Overall HPV prevalence: significant difference in the overall HPV
prevalence between the two cohorts in age-groups of 30–39, 40–49
and 50–59 (p,0.001, p,0.001 and p=0.007, respectively, z test). (B)
High-risk HPV prevalence: significant difference in the high-risk HPV
prevalence between the two cohorts in age-groups of 30–39 and 40–49
(p,0.001 and p,0.001, respectively, z test). The error bar indicates 95%
confidence interval.
doi:10.1371/journal.pone.0019244.g001
HPV Prevalence in Southern China
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19244
and 16% of the overall HPV positive cases. The highest
prevalence of multiple HPV infections was also found in 20–29
age-group (4.2%) and $60 age-group (3.6%) in the HK cohort,
whereas the prevalence was appeared to be the highest in the 20–
29 age-group (3.2%) in the GZ cohort, while it declined in other
age-groups (2.7%, 1.2%, 2.5% and 1.2% in age-groups of 30–39,
40–49, 50–59, $60, respectively).
HPV type-specific prevalence
The HPV type-specific prevalence was also different between
the two cohorts. While HPV16 being the most common high-risk
HPV type (1.24%, 95% CI: 0.75–1.73%, Table 1) identified in the
HK cohort, HPV52 was the most prevalent in the GZ cohort
(2.62%, 95% CI: 1.75–3.48%). The two HPV types contributed to
be the most common high-risk types in the two cohorts. The seven
most common high-risk HPV types observed in the HK cohort
were HPV16, 52, 58, 18, 33, 68 and 45 (in descending order) and
in the GZ cohort were HPV52, 16, 31, 58, 18, 33 and 68 (in
descending order), respectively (Table 1). HPV31 was not detected
in HK cohort and the HPV52 prevalence in the GZ cohort was
significantly higher than that in the HK cohort (p = 0.004).
Risk factors for HPV infection
Potential risk factors in relation to overall HPV infection were
also examined. Age was found to be a significant risk factor
associated with HPV infection in the HK cohort (p = 0.005,
Table 2). Women in the 20–29 age-group had significantly higher
risk for HPV infection compared to 30–39 and 40–49 age-groups
(OR=0.39, 95% CI: 0.19–0.8 and =0.42, 95% CI: 0.18–0.98,
respectively). On the other hand, only 16% of women in the HK
cohort had no previous cervical smear test and these women had a
trend of having higher risk for HPV infection (OR=1.82 95%CI:
0.99–3.34) than those having history of the smear test performed;
however, the association did not reach statistical significant level.
Similarly, despite not reaching the statistical significant level,
women lacking previous cervical smear test in the GZ cohort
tended to have higher risk for HPV infection (OR=1.43, 95% CI:
0.97–2.11).
Sexual behaviour factor, the lifetime number of sexual partners
was found to be associated with the risk of HPV infection in the
GZ cohort (Table 2). Women with more than two lifetime sexual
partners were found to have significant higher risk for HPV
infection than women with 1–2 sexual partners (OR=2.61, 95%
CI: 1.20–5.68, p = 0.041). Increase of number of sexual partners
tended to have increase of HPV infection risk in the HK cohort
(ORs for 2 and $3 lifetime sexual partners were 1.12 and 1.19);
however, the difference was not statistically significant. Another
sexual behaviour factor, age at first sexual intercourse was found
not significantly associated with HPV infection risk in both studied
cohorts.
The reproductive factors analyzed in the present study seemed
to have no influence in HPV infection risk in both cohorts. Ever
being pregnant or number of pregnancies, number of abortions,
condom and oral contraceptive use had no significant association.
Having previous sexually transmitted disease (STD) and being
smoker tended to have increase of HPV infection risk, however
they did not reach statistical significance. Furthermore, the level of
education was not a risk factor for HPV infection in both of the
study cohorts.
Discussion
Our cross-sectional study examined and compared the HPV
prevalence in women residing in HK and GZ. The age-adjusted
prevalence of HPV infection in women with normal cytology in
the HK cohort was significantly lower than that in the GZ cohort
(6.2% vs 10%, p,0.001), and this might partly be attributed to the
difference in sample population. Samples recruited in HK were
from women with regular cervical screening, while samples in GZ
were from women without or with only opportunistic cervical
screening due to lack of cervical screening programme there. The
HPV prevalence in the HK cohort was also lower than the
previously reported worldwide data of 10.4% (95% CI 10.2–10.7),
Table 1. The prevalence of type-specific HPV infection in women with normal cytology in the HK and GZ cohorts.
Hong Kong Guangzhou
HPV type No. of positive case Prevalence** (95%CI) No. of positive case Prevalence** (95%CI) P value*
16{{ 25 1.24% (0.75–1.73) 21 1.19% (0.63–1.76) 0.901
18{{ 20 0.99% (0.56–1.43) 9 0.68% (0.22–1.15) 0.339
31{ 0 0 27 1.16% (0.67–1.66) ,0.001*
33{{ 5 0.25% (0.03–0.47) 10 0.59% (0.2–0.98) 0.136
35 0 0 1 0.07% (0.0–0.21) 0.317
39 1 0.04% (0.0–0.12) 6 0.32% (0.03–0.6) 0.07
45{ 3 0.15% (0.0–0.31) 3 0.24% (0.0–0.54) 0.577
51 0 0 2 0.14% (0.0–0.35) 0.198
52{{ 23 1.16% (0.68–1.64) 40 2.62% (1.75–3.48) 0.004*
56 0 0 4 0.27% (0.0–0.54) 0.058
58{{ 20 1.03% (0.58–1.48) 18 1.07% (0.53–1.62) 0.905
59 2 0.09% (0.0–0.21) 2 0.15% (0.0–0.37) 0.619
68{{ 5 0.23% (0.03–0.44) 7 0.39% (0.06–0.72) 0.428
*Statistically significant at 0.05 level of significance by Holm’s procedure that accounts for the multiple comparisons.
**Adjusted for the stratified sampling design.
{The seven commonest HPV high-risk types in the HK cohort.
{The seven commonest HPV high-risk types in the GZ cohort.
doi:10.1371/journal.pone.0019244.t001
HPV Prevalence in Southern China
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19244
Table 2. Potential risk factors in relation to HPV infection in the HK and GZ cohorts.
Hong Kong1 (N=1330) Guangzhou2 (N=1233)
Variables
No. of
case (%)
No. of
HPV+ OR3 (95% CI)
P
value3
No. of
case (%)
No. of
HPV+ OR3 (95% CI)
P
value3
Age (years) 0.005 0.688
20–29 298 (22.4) 37 1 236 (19.1) 36 1
30–39 260 (19.5) 13 0.39 (0.19–0.8) 240 (19.5) 34 1.25 (0.68–2.27)
40–49 252 (18.9) 12 0.42 (0.18–0.98) 231 (18.7) 27 1.06 (0.55–2.05)
50–59 262 (19.7) 16 0.67 (0.27–1.7) 271 (22) 38 1.45 (0.74–2.83)
)60 258 (19.4) 25 1.3 (0.5–3.4) 255 (20.7) 30 1.06 (0.52–2.14)
Screening history 0.054 0.075
Pap smear 1114 (83.8) 79 1 384 (31.1) 41 1
No Pap smear 216 (16.2) 24 1.82 (0.99–3.34) 849 (68.9) 124 1.43 (0.97–2.11)
Lifetime number of
sexual partners
0.877 0.041
1 919 (69.1) 63 1 1063 (86.2) 131 1
2 202 (15.2) 18 1.12 (0.59–2.13) 124 (10.1) 20 1.42 (0.81–2.48)
)3 209 (15.7) 22 1.19 (0.59–2.36) 46 (3.7) 14 2.61 (1.2–5.68)
Age at first intercourse 0.351 0.842
(20 469 (35.3) 50 1 177 (14.4) 27 1
21–25 536 (40.3) 31 0.67 (0.39–1.18) 654 (53) 90 1.07 (0.64–1.79)
)26 325 (24.4) 22 0.86 (0.44–1.69) 402 (32.6) 48 0.95 (0.51–1.76)
Gravidity 0.115 0.884
0 391 (29.4) 29 1 88 (7.1) 17 1
1–2 494 (37.1) 44 1.13 (0.55–2.34) 563 (45.7) 70 0.91 (0.4–1.64)
3–4 344 (25.9) 26 0.69 (0.25–1.85) 459 (37.2) 61 0.92 (0.39–2.17)
)5 101 (7.6) 4 0.28 (0.06–1.22) 123 (10) 17 0.92 (0.3–2.79)
Number of abortion 0.097 0.187
0 884 (66.5) 59 1 388 (31.5) 61 1
1–2 407 (30.6) 42 1.82 (1.03–3.22) 691 (56) 80 0.67 (0.43–1.05)
)3 39 (2.9) 2 1.1 (0.21–5.9) 154 (12.5) 24 0.8 (0.38–1.69)
Condom use 0.122 0.604
Never or rare 717 (53.9) 64 1 899 (72.9) 123 1
Regular 613 (46.1) 39 0.7 (0.45–1.1) 334 (27.1) 42 0.9 (0.6–1.35)
Oral contraceptives 0.126 0.556
Never 595 (44.7) 40 1 1055 (85.6) 139 1
Ever 735 (55.3) 63 1.42 (0.91–2.24) 178 (14.4) 26 1.15 (0.72–1.85)
History of STD 0.259 0.204
Never 1309 (98.4) 99 1 1214 (98.5) 159 1
Ever 21 (1.6) 3 2.14 (0.57–8.04) 19 (1.5) 6 2.02 (0.68–6.0)
Smoking 0.96 0.98
Never 1175 (88.3) 79 1 1197 (97.1) 158 1
Former 79 (5.9) 8 0.97 (0.42–2.24) 17 (1.4) 3 1.03 (0.28–3.87)
Current 76 (5.7) 9 0.89 (0.38–2.05) 19 (1.5) 4 1.13 (0.33–3.9)
Education 0.493 0.55
Nil/primary 289 (21.7) 21 1 135 (10.9) 20 1
Secondary/post-secondary 717 (53.9) 59 1.13 (0.59–2.15) 597 (48.4) 75 0.9 (0.51–1.61)
College/University & above 324 (24.4) 23 0.81 (0.35–1.86) 501 (40.6) 70 1.12 (0.6–2.09)
1:Tolerance .0.4 for all variables, Naglekerke R2 = 7.8%, Hosmer-Lemeshow test p = 0.793.
2:Tolerance .0.4 for all variables, Naglekerke R2 = 3.5%, Hosmer-Lemeshow test p = 0.750.
3:OR and P-value were obtained using multivariate logistic regression analysis model of which included all of the variables listed in this table. Bold type indicated
statistically significant values.
N: Total number of cases.
doi:10.1371/journal.pone.0019244.t002
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but similar to those areas with lower HPV prevalence in the Asia
region, such as Thailand, Philippines and India [18]. The age-
adjusted HPV prevalence (10%) in the GZ cohort was comparable
to the results obtained in other regions of mainland China, such as
Shanxi [7,19,20]. Besides the prevalence, the age-specific infection
patterns were also different between our two studied cohorts.
Younger women (20–29 years old) in the GZ cohort had the
highest infection and the prevalence was decreased with increasing
age, whereas a bimodal distribution of HPV prevalence was
observed in age-groups of 20–29 and $60 in the HK cohort.
Similar to the other part of world, the highest HPV prevalence was
seen in the youngest age group in our study, suggesting a higher
possibility of acquiring HPV infections at younger ages [21].
Our findings in the HK cohort was also in-line with the
reported meta-analysis study showing that HPV infection was
most common in young age women (,30 years) and a second peak
in women aged 45 or older [18]. The second peak in the HK
cohort started late, from 60 years of age. This two-peak pattern is
the predominant prevalent curve reported in women with normal
cytology worldwide [18]. The phenomenon has been hypothesized
to be the results of reactivation of latent infections due to impaired
immune response, or changes in sexual behaviors in women and
their partners [18]. However, the second peak was not obvious in
our GZ cohort. HK and GZ are in closed neighbourhood, the
different socioeconomic environment, such as lifestyle and living
standards are different between the two regions. This may explain
the difference in prevalence pattern. HK used to be a British
colony before 90 s. It is a well developed city and the economic
and social lives are closely related to those in the Western
countries. The prevalence curve in the GZ cohort was also
different from those from central and northeastern parts of
mainland China, such as Shanxi and Shenyang, where high HPV
prevalence was seen across all age groups [7,22]. The relatively
low HPV prevalence compared to other cities in China and the
different prevalence pattern observed in GZ may be explained by
a relatively low cervical cancer burden in that area [19].
Our current study assessed HPV type-specific prevalence across
a broad age-range of the women in Southern China. The type-
specific HPV prevalence was also found to be different between
the two study cohorts. HPV16 remained to be the most common
high-risk type in HK, whereas HPV52 was the most frequently
found in the GZ cohort. Our findings were in concordance with
the previous reports from some Asian countries where the HPV52
and HPV58 infections were as common as HPV16 infection
[23,24]. Indeed, the infection rate of HPV52 was second to that of
HPV16 in the HK cohort, and HPV58 ranked third and fourth in
HK and GZ, respectively. There was a significantly higher
prevalence of HPV31 in the GZ cohort when compared to that in
the HK cohort.
Having previous cervical cancer screening was found to be
important in relation to HPV infection in the HK cohort.
Although such association was not observed in the GZ cohort,
women lacking previous cervical smear was found to be associated
with the higher HPV prevalence (Table 2). This suggests that those
who do not attend for regular smears test may belong to a group of
women with high risk for HPV infection and development of
cervical cancer. It is therefore important to identify this group of
women and try to target the cervical screening promotion at them.
Various aspects of sexual behaviour were reported to be related
to the acquisition of HPV infection. In the present study, only the
lifetime number of sexual partners was associated with HPV
infection risk in the GZ cohort. Women having three or more
lifetime sexual partners had significantly higher risk of HPV
infection, suggesting that sexual behaviour, as elsewhere
[22,25,26], is an important determinant of HPV infection,
particularly in the GZ region. The more sexual partners that a
woman has, the higher risk of getting infected with one or more
HPV types over time. There was no significant association with
the number of sexual partners in the HK cohort for HPV infection
risk, and the result was different from other local studies, where
lifetime number of sexual partners was shown to be an
independent risk factor [12,27]. This may be attributed to the
difference in the study population; their study population included
women regardless of their cytological findings, whereas only
women with normal cytology were included in our study. Since
HPV is mainly sexually transmitted, information on the sexual
behaviours of the sexual partners may help to explain the
difference findings between the two cohorts. Unfortunately, no
such information was available at the present study.
Results of the studies regarding the effect of smoking on HPV
infection have been inconsistent; some showed that smoking was
associated with an increased prevalence of HPV [28,29], but not
others [30–33]. We found an increased trend of HPV prevalence
in current smokers compared to non-smokers in both cohorts.
However, the numbers of current and former smokers at either
cohort were not sufficiently large to draw a conclusive finding.
Similar situation was also encountered in the association analysis
of history of STD in both cohorts.
In conclusion, the overall and type-specific HPV prevalence
were different between the HK and GZ cohorts. A difference
pattern of the age-specific HPV prevalence was also observed in
the two cohorts. Such difference could be due to the difference in
life style and socio-economic status between these two neighboring
regions. Young age was the most prominent independent risk
factor for HPV infection in the HK cohort, while the lifetime
number of sexual partner was found to be the infection risk factor
in the GZ cohort. Our findings would enhance the understanding
of the epidemiology of HPV infection in the two regions, and the
information will assist in developing a constructive screening
program, the choice of HPV types to be included in the
development of the HPV vaccine in future to provide protection
against those high-risk types of HPV with high prevalence
identified in our cohorts, but not included in the current existing
HPV vaccines.
Materials and Methods
Ethics statement
The study was approved by the local Institutional Reviewer
Board of the University of Hong Kong/Hospital Authority of
Hong Kong Western Cluster (HKU/HA HKW IRB, Ref#
UW04-267T/589). All participants provided voluntary written
informed consent. Information sheets and written consent forms
were available in Chinese and English to ensure comprehensive
understanding of the study objectives, potential risks, and benefits.
Study design and sample collection
This was a cross-sectional study between the regions of HK and
GZ, China, and was collaboratively conducted amongst Depart-
ments of Obstetrics & Gynaecology and Pathology of the
University of Hong Kong (HKU), the Family Planning Association
of Hong Kong (FPAHK), and Department of Obstetrics &
Gynaecology, Second Affiliated Hospital of Sun Yat-Sen Univer-
sity (SYSU), GZ, during the period of January 2007–April 2008.
In HK, cytology samples were collected from women attending
the clinic in FPAHK for routine cytological screening. Participants
were interviewed by a trained interviewer using a standardized
questionnaire to elicit information on the demographic variables,
HPV Prevalence in Southern China
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cervical screen history, sexual behaviours, contraceptive practice,
reproductive history and smoking habits. Informed consent was
obtained from each participant. The recruitment was designed to
obtain an age-stratified sample groups including at least 250
women in each of the 10-year age group from 20–29, 30–39, 40–
49, 50–59, 60 and older. In GZ, similar procedures were carried
out and cytology samples were collected from healthy women
attending the out-patient clinic in the Department of Obstetrics &
Gynaecology, Second Affiliated Hospital of SYSU.
All participants underwent a pelvic examination by a gynae-
cologist or a trained nurse. The exfoliated cervical cells were
collected by ThinPrepTM (in HK) or LCT (in GZ) liquid-based
cervical cytology test. The cytological screening tests were
performed by the cervical cytology laboratories at the Department
of Pathology, HKU and SYSU, respectively.
HPV detection and genotyping
DNA extraction and HPV genotyping tests were performed in
respective institutes where the specimens were collected. DNA was
extracted from the cytological remnants, and HPV DNA was
detected and genotyped using a commercial GenoArray HPV
Genotyping Test (Hybribio, Ltd, Hong Kong) [34].
HPV GenoArray Test is a PCR-based assay and capable of
amplifying 21 HPV genotypes including 13 HR types (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 68). The assay was performed
according to manufacturer’s protocol. Briefly, after PCR ampli-
fication, the amplicons were subjected for hybridization. The assay
utilized a ‘‘flow-through hybridization’’ technique by actively
directing the targeting molecules toward the immobilized probes
within the membrane fibers, and the complementary molecules
were retained by forming duplexes. The hybrids were then
detected by the addition of streptavidin-horseradish peroxidase
conjugate and a substrate (NBT/BCIP). The provided positive
control and two negative controls (HPV negative C33-A cells and
PCR water) were included in each set of PCR to assess the
performance of the test.
Statistical analysis
HPV types were categorized by oncogenicity: HPV16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 were categorized as high-
risk type (HR) and other types were grouped as other risk types.
The age-specific general population of HK in 2006 and GZ in
2003 (the latest data available) were used in the calculation of the
HPV infection prevalence and the age distribution of women with
normal cytology was assumed to be similar to the general
population. The prevalence of overall HPV infections, type-
specific HPV infections and multiple infections as well as their
corresponding 95% confidence intervals (CIs) among HK and GZ
women with normal cytology were estimated after taking account
of the stratified random sampling design [35]. The HPV
prevalence between the HK and GZ cohorts were compared by
a z-test. Multicity was accounted by using the Holm’s procedure
[36]. The effects of epidemiologic variables on HPV infection in
women with normal cytology were assessed by univariable and
multivariable logistic regression with age-groups of 10 years
interval (20–29, 30–39, 40–49, 50–59, 60 and up) independently
in the HK and GZ cohorts, and the odd ratios and their 95% CIs
were calculated. Multi-collinearity in the multivariable analysis
was assessed by examining the tolerance and the goodness of fit of
the logistic models were assessed by the Hosmer-Lemeshow test. A
P-value,0.05 was regarded as statistically significant. The
statistical analysis was performed using SPSS version 16.0.
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